Isotopia, CPDC ink manufacturing deal for lutetium-177

AuntMinnie.com staff writers

Sep 7, 2020

2019 12 19 00 53 5252 Hands Shaking Deal 400

Isotopia Molecular Imaging of Israel has signed a production agreement for no-carrier-added lutetium-177 (n.c.a. Lu-177) with radiopharmaceutical manufacturer Centre for Probe Development and Commercialization (CPDC) of Canada.

CPDC will produce n.c.a. Lu-177, which is used in targeted radionuclide therapy, in collaboration with Isotopia for distribution in North America, according to the companies.

        An unexpected error occurred: Network error: Response not successful: Received status code 500

            [
  {
    "message": "Cannot execute GraphQL operations after the server has stopped.",
    "extensions": {
      "code": "INTERNAL_SERVER_ERROR"
    }
  }
]

PET/CT reveals new infections in ICU patients

F-18 FDG-PET/CT is a valuable approach for diagnosing unknown infections in intensive care unit (ICU) patients.

February 21, 2025

There are several conceivable advantages of F-18 FDG PET/CT over conventional imaging. Image A and B showing an example of the distinctive capability of the F-18 FDG PET/CT. A shows a fusion image of F-18 FDG PET/CT and low-dose CT and B an high resolution chest CT of a patient with an Aspergillus infection. The suspected aspergilloma is concealed on the high resolution CT due to the lung fluids and consolidation. Image C and D (fusion image of F-18 FDG PET/CT and low-dose CT and low-dose CT only, respectively) are examples of the ability to image inflammation while no concurrent abnormalities are visualized, in this case prostatitis (red arrows). Image E, a maximized intensity projection of F-18 FDG PET, shows a patient with lung infections and multiple muscle abscesses after MRSA sepsis. This is an illustrative example of a relevant dissemination investigation. Image and caption available for republishing under Creative Commons license (CC BY 4.0 DEED, Attribution 4.0 International) and courtesy of Annals of Intensive Care.

PSMA-PET tracer performs well in clinical trial

PET/CT imaging with a new gallium-68-based prostate cancer radiotracer shows promise for detecting recurrent metastatic disease.

February 20, 2025

(A) Representative maximum-intensity projection and selected PET/CT images (fused, PET and CT only) of patient with metastatic prostate cancer at 1 hour after injection. (B and C) Low uptake of Ga-68 PSMA-R2 in salivary and submandibular glands is also demonstrated. (D) Images show heterogeneous uptake of Ga-68 PSMA-R2 with varying degrees of intensity in multiple spine bone lesions (vertebral sclerotic lesion with intense PSMA-R2 expression at its periphery indicated with red arrow). HU = Houndsfield unit; SUVbw = body-weight SUV. Images and caption courtesy of the Journal of Nuclear Medicine.

New PET tracer developed for breast cancer

A new PET radiotracer shows promise for diagnosing triple-negative breast cancer.

February 14, 2025

Ga-68 FZ-NR-1 PET/CT images and F-18 FDG PET/CT and PET/MRI images in representative nectin-4-positive TNBC patients. (A) PET/CT images and nectin-4 immunohistochemistry (IHC) staining of patient 1. Maximum-intensity projection (MIP) images and axial and coronal PET/CT images of Ga-68 FZ-NR-1 and F-18 FDG both showed high uptake in lung metastases (arrow). (B) PET/CT images and nectin-4 IHC staining of patient 2. MIP images and axial and coronal PET/CT images of Ga-68 FZ-NR-1 showed high uptake in recurrence of right breast cancer after surgery (arrow), and those of F-18 FDG PET/MRI showed high uptake. Image courtesy of the Journal of Nuclear Medicine.

Pluvicto safe in patients with impaired kidneys

Lu-177 prostate-specific membrane antigen-617 (Lu-177 PSMA-617, Pluvicto) may be safely delivered in patients with impaired renal function.

February 13, 2025

Dosimetry key in Lu-177 cancer therapy

Personalized medicine is rapidly evolving in cancer theranostics, with technology now available that allows clinicians to optimize doses of radiopharmaceuticals on an individual patient level, according to experts.

February 5, 2025

Kesner Zanzonico

PET/CT guides surgery for primary aldosteronism

PET/CT imaging with gallium-68 pentixafor can effectively guide surgery for patients with primary aldosteronism, a common cause of hypertension.

January 30, 2025

Apa 679bd41fd4afc Thumbnail

New guidance issued on FAP-PET imaging

Top U.S. and European nuclear medicine organizations have issued joint guidelines on the use of fibroblast activation protein (FAP)-PET imaging in cancer patients.

January 27, 2025

Is herpes infection protective in early Alzheimer’s disease patients?

In a recent PET study with “unexpected” results, patients infected with herpes had fewer signs of brain deposits associated with Alzheimer’s disease than uninfected patients.

January 24, 2025

What brain mechanisms drive depression in older adults?

PET has revealed that mechanisms other than amyloid brain deposits may underlie depressive symptoms in people later in life.

January 23, 2025

PET/CT can rule out CAV in heart transplant patients

Cardiac PET/CT scans can effectively rule out moderate to severe cardiac allograft vasculopathy (CAV) in heart transplant patients.

January 17, 2025

FAPI-PET shows promise for imaging gastric cancers

Gallium-68 fibroblast activation protein inhibitor (FAPI) PET/CT is a promising new method for imaging gastric cancer.

January 16, 2025

Fapi Pet Gastric Cancer Thumbnail

PET tracks long-term changes in patients with dementia

PET imaging can assess brain metabolism changes over time in individuals with prodromal dementia with Lewy bodies (DLB) and probable DLB.

January 13, 2025

Page 1 of 600